|
MDGL | Madrigal Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.05 |
| Leverage | 57.92% |
| Market Cap | $ 10.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -324.5m |
| Margin | -25.40% |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.